- Home
- RCEL vs MIST Comparison
RCEL vs MIST Comparison
Compare RCEL & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCEL
- MIST
- Stock Information
- Founded
- RCEL N/A
- MIST 2003
- Country
- RCEL United States
- MIST Canada
- Employees
- RCEL N/A
- MIST N/A
- Industry
- RCEL Medical/Dental Instruments
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- RCEL Health Care
- MIST Health Care
- Exchange
- RCEL Nasdaq
- MIST Nasdaq
- Market Cap
- RCEL 158.1M
- MIST 132.5M
- IPO Year
- RCEL N/A
- MIST N/A
- Fundamental
- Price
- RCEL $5.16
- MIST $1.43
- Analyst Decision
- RCEL Strong Buy
- MIST Strong Buy
- Analyst Count
- RCEL 4
- MIST 2
- Target Price
- RCEL $16.50
- MIST $7.50
- AVG Volume (30 Days)
- RCEL 271.4K
- MIST 2.9M
- Earning Date
- RCEL 08-07-2025
- MIST 08-15-2025
- Dividend Yield
- RCEL N/A
- MIST N/A
- EPS Growth
- RCEL N/A
- MIST N/A
- EPS
- RCEL N/A
- MIST N/A
- Revenue
- RCEL $71,661,000.00
- MIST N/A
- Revenue This Year
- RCEL $57.16
- MIST N/A
- Revenue Next Year
- RCEL $36.69
- MIST N/A
- P/E Ratio
- RCEL N/A
- MIST N/A
- Revenue Growth
- RCEL 41.35
- MIST N/A
- 52 Week Low
- RCEL $4.71
- MIST $0.63
- 52 Week High
- RCEL $14.16
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- RCEL 41.82
- MIST 40.51
- Support Level
- RCEL $5.59
- MIST $1.42
- Resistance Level
- RCEL $6.15
- MIST $1.64
- Average True Range (ATR)
- RCEL 0.43
- MIST 0.11
- MACD
- RCEL -0.02
- MIST -0.03
- Stochastic Oscillator
- RCEL 9.85
- MIST 8.95
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).